Ugur Sahin, BioNTech CEO (Andreas Arnold/picture-alliance/dpa/AP Images)
Flexing its newfound wealth, BioNTech snaps up a TCR platform and manufacturing site as Gilead exits
BioNTech is putting some of its new-found wealth from its star mRNA vaccine for Covid-19 to use. The biotech $BNTX, which now weighs in with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
